Relmada Therapeutics (RLMD) Misses Q3 EPS by 4c

Relmada Therapeutics (NASDAQ: RLMD) reported Q3 EPS of ($0.72), $0.04 worse than the analyst estimate of ($0.68).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Wolfspeed (WOLF) Misses Q4 EPS by 174c; Offers Guidance
• Coty (COTY) Misses Q4 EPS by 1c, offers outlook